The purpose of the webcast is to discuss the results of the second set of Phase 2 data on ISIS-APOCIII Rx, triglycerides drug. This is the second of three sets of Phase 2 data on APOCIII Rx that they planned to report this summer. As you recall, they presented the first set of data at the ATA Meeting and in a webcast in June.
Management quotes" The most important new observation from the current study is that ISIS-APOCIIIRx is additive to fibrates, one of the classes of drugs used to treat patients with high triglycerides. The emerging profile of ISIS-APOCIIIRx I think reports our enthusiasm for the drug. Let me first remind you that we believe ISIS-C3RX could be used either as a single agent on combination with existing drugs used to treat patient with high triglycerides. So, the study we're presenting today, is an important step because it confirms that ApoC-III Rx can be used in combination with fibrates."
Transcript here
Management quotes" The most important new observation from the current study is that ISIS-APOCIIIRx is additive to fibrates, one of the classes of drugs used to treat patients with high triglycerides. The emerging profile of ISIS-APOCIIIRx I think reports our enthusiasm for the drug. Let me first remind you that we believe ISIS-C3RX could be used either as a single agent on combination with existing drugs used to treat patient with high triglycerides. So, the study we're presenting today, is an important step because it confirms that ApoC-III Rx can be used in combination with fibrates."
Transcript here
Tidak ada komentar:
Posting Komentar